(87%) and 41 (72%) of group B received adjuvant chemotherapy. All pts with hormone receptor positive BC were treated with adjuvant hormonal therapy in both groups. 12 pts (21%) of group A reported local recurrence as first invasive event versus 6 pts of group B (15%); 9 pts of group A and all pts of group B developed distant metastasis. In overall population DFS was 53.6 months (95% CI; 40.4 À 66.8), no statistically significant different was noticed among two groups: 56.2 mos group A, 49.8 group B (p ¼ 0.3). OS was 120.2 mos, (95% CI; 112 À 311.9) with statistically significant difference among two groups: 137.7 mos group A, 98.7 mos group B (p ¼ 0.03). Conclusions: the study demonstrated that a LNR > 0.19 was associated with a significant increased risk of death, independently from tumor characteristics or type of treatment received. Despite the limitations of a retrospective study on a small sample of pts, results obtained should encourage to identify a more accurate cut-off for LNR that could help clinicians for therapeutic decisions or follow up programs.
C48
Response rate by molecular subtypes and p53 expression in neoadjuvant therapy for breast cancer with TAC regimen: a singlecentre experience Background: Pathologic complete response (pCR) is a surrogate of survival in breast cancer (BC), although its value seems to be restricted to specific subtypes. The aims of our study were to determine the response rate (RR) and pCR according to BC subtypes and p53 expression in neoadjuvant setting. Materials and methods: From January 2000 to December 2016 we retrospective analyzed 87 consecutive patients (pts) treated with TAC regimen (docetaxel 75mg/mq, doxorubicin 50mg/mq, cyclophophamide 500mg/mq, d1q21) for locally advanced BC between 2004 and 2016. RR > 50% and pCR (defined as no evidence of residual cancer or residual in situ component only in the primary tumour and lymph-nodes) were compared to St. Gallen 2015 molecular subtypes and p53 expression, considered positive with a nuclear staining>10%. Background: Chemotherapy used for the treatment of breast cancer (BC) is commonly complicated by cardiac damage and may also deteriorate vessels function, leading to an impaired cardiovascular coupling. Cardiac toxicity is generally evaluated by assessing left ventricular (LV) ejection fraction (EF). Recently, myocardia deformation imaging has been proposed for the detection of subtle systolic dysfunction. However, few studies have analyzed the effects of anticancer drugs through an integrated evaluation of heart and vessels. The aim of the study was to evaluate myocardial and arterial function early after anthracyclines administration. Patients and methods: 35 women (mean age: 54610) with localized or metastatic BC and without history of heart disease were enrolled. All patients received anthracyclines (epirubicin, 500 mg/mq or doxorubicin 600 mg/mq) and, in different percentages, further antiblastic therapy: 5-fluorouracil (500 mg/mq, 35.7%), docetaxel (75 mg/mq, 42.9%), cyclophosphamide (600 mg/mq, 89.3%) and trastuzumab (loading dose of 8 mg/kg, followed by 6 mg/kg, 25%). Patients were evaluated at time 0, 3 and 6 months after the start of the therapy. We used global longitudinal strain (GLS, EchoPac), as marker of preclinical LV systolic dysfunction, and pulse wave velocity (PWV), augmentation index (AI), and b-stiffness, derived by echotracking software (Aloka, Japan) as markers of arterial stiffness, measured on the carotid arteries. The ANOVA analysis was used for comparing the data.
Results: Although volumes, EF and BNP were not altered significantly after cancer therapy, GLS and troponin I were instead modified since the first 3 months (Tab. 1). Also, both carotid PWV and b-stiffness index increased at 6 months. Results were not affected by the type of anticancer drugs associated with antracyclines. Conclusions: A combined evaluation of cardiac and vascular function should be early started in patients receiving anthracyclines. The identification of early markers of cardiac damage from cytotoxic drugs remains of crucial clinical relevance. Background: Previous studies have suggested that scalp cooling may prevent chemotherapy-induced alopecia, a common adverse event with a relevant impact on quality of life. Patients and methods: Two DigniCap scalp cooling system devices are available at the Istituto Oncologico Veneto. The PROTECT prospective observational study evaluated the performance of scalp cooling for patients with breast cancer receiving different adjuvant/neoadjuvant chemotherapy schedules. Scalp cooling was initiated 30 minutes prior to each cycle, with a scalp temperature maintained at 3-5 C, throughout chemotherapy and for 90 to 120 minutes afterwards. Patients' questionnaires were administered every 3 weeks during treatment and at 3 weeks from the last cycle. Success of scalp cooling was defined as self-reported hair loss 50% according to Dean scale. Results: From may to december 2016, 40 patients were included in these treatment cohorts: n ¼ 10, Docetaxel-Cyclophosphamide q3w x4 (TC); n ¼ 10, Paclitaxel qw x12 (Txl); n ¼ 10 Epirubicin-Cyclophosphamide q3w x4 followed by Txl qw x12 (EC-Txl); n ¼ 10, Txl qw x12 followed by EC q3w x4 (Txl-EC). HER2 þ (n ¼ 11) patients received trastuzumab. Success rate at 3 weeks from the start of treatment was 85% (34/40). Three patients in the TC and 3 in the EC-Txl cohort reported a hair loss >50%. Full assessments have been completed so far in the TC, Txl and EC-Txl cohorts (3 patients in the Txl-EC cohort are still undergoing chemotherapy). Rate of final scalp cooling success was 18/30 (60%). No failure was reported in the Txl cohort. Failure was reported by 6 patients in the TC and 6 patients in the EC-Txl cohort and led to premature scalp cooling discontinuation in 1 and 3 patients, respectively. Two more patients discontinued scalp cooling in these cohorts: 1 patient due to chemotherapy toxicity and 1 patient in the EC-Txl cohort due to low scalp cooling tolerability. Most frequent cooling-related symptoms were: chill(26/30), heavy head(18/30), scalp pain(14/30), headache(13/30); respective mean highest scores (in a self-reported scale of 1 to 4 with 4 as the worst) were: 3.04, 2.39, 2.64, 2.54. Mean final patient's judgment on scalp cooling performance (on a scale of 1 to 7, where 7 is the best) was 6.7, 5 and 4.6 in the Txl, TC and EC-Txl cohorts, respectively. Conclusions: Use of scalp cooling system for chemotherapy-induced alopecia prevention was successful in the majority of patients, but relevant difference was observed across treatment groups. Patients and methods: Data on women with breast cancer stage I-IV who used the Paxman scalp-cooler during chemotherapy at Ferrara Oncology Unit were prospectively collected. Efficacy and safety of scalp-cooling device were assessed using clinicians-reported data and patients direct interviews. Alopecia was graded according to the Dean's Scale: a score of 0 to 2 (hair loss < 50%) was considered successful.
Correlation between categorical variables was assessed using chi-square test and Fisher's exact test. Results: From March 2015 to April 2017, 48 women with a median age of 53 underwent scalp-cooling during chemotherapy for breast cancer. 5 patients (pts) were treated in neoadjuvant setting, 29 in adjuvant setting and 14 in advanced setting; 27 pts received anthracycline-based chemotherapy, 13 taxane-based chemotherapy, 5 both anthracyclines and taxanes and 3 other regimens. Median scalp-cooling cycles were 3 (range 1-14). Hair preservation was reported in 17 women (37%). According to literature data, women treated with taxane-based chemotherapy had higher rate of hair preservation than women treated with anthracycline-based chemotherapy (54% vs 31%), even if the correlation between chemotherapy regimen and hair loss wasn't statistically significant in our analysis. Different variables (such as age, BMI, smoke, menopausal status, comorbidities, previous chemotherapy, neutropenia) were tested, but only neutropenia G3-4 during treatment resulted significantly related to hair loss (chi-square 4.9, p 0.049). Early interruption of scalp-cooling occurred in 26 pts, due to hair loss < ¼ grade 3 (21 pts) or intolerance (5 pts). 15 pts reported adverse events, all graded < ¼ 2, the most common being headache, cold sensation and mild cranial pressure. 14 pts had to use a wig, even if 5 of them experienced alopecia G1-2. No scalp metastases were reported, but follow-up data are still immature. Conclusions: Our analysis suggests that scalp-cooling has a moderate efficacy in reducing CIA and is well-tolerated. Further clinical trials are needed to determine exact indicationts for scalp-cooling and to improve the efficacy and adherence, to reduce sideeffects and to define the best cooling procedure.
